PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells
Authors
Keywords
Mesothelin, Chimeric antigen receptor T, Programmed cell death protein 1, Short hairpin RNA, Immunotherapy
Journal
HUMAN IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2020-12-17
DOI
10.1016/j.humimm.2020.12.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
- (2020) Elham Masoumi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
- (2020) Le Qin et al. Biomarker Research
- Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes
- (2019) Yanheng Wu et al. Nanomedicine
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
- (2019) Jiang Lv et al. Journal of Hematology & Oncology
- PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
- (2019) Jianshu Wei et al. Journal for ImmunoTherapy of Cancer
- CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer
- (2019) Ryan Zander et al. IMMUNITY
- CRISPR/Cas9-mediated knockout of DGK improves anti-tumor activities of human T cells
- (2018) In-Young Jung et al. CANCER RESEARCH
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells
- (2018) Hamid Reza Mirzaei et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
- (2018) Xingliang Guo et al. Frontiers in Pharmacology
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical trials of CAR-T cells in China
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
- (2016) M Thorn et al. CANCER GENE THERAPY
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
- (2016) Qi Zhang et al. OncoImmunology
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2016) Shu Su et al. Scientific Reports
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
- (2015) Anish Thomas et al. Oncotarget
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Production, purification and titration of a lentivirus-based vector for gene delivery purposes
- (2014) Masoud Nasri et al. CYTOTECHNOLOGY
- Hepatic Immune Regulation and Its Involvement in Viral Hepatitis Infection
- (2014) Percy A. Knolle et al. GASTROENTEROLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Strength of PD-1 signaling differentially affects T-cell effector functions
- (2013) F. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RNAi Therapeutics: The Teenage Years
- (2012) Jeffrey Perkel BIOTECHNIQUES
- Mesothelin, a novel immunotherapy target for triple negative breast cancer
- (2012) Julia Tchou et al. BREAST CANCER RESEARCH AND TREATMENT
- Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
- (2012) T Einama et al. BRITISH JOURNAL OF CANCER
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
- (2012) E. L. Servais et al. CLINICAL CANCER RESEARCH
- Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy
- (2012) Piotr Maczuga et al. MOLECULAR THERAPY
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
- (2011) Uddalak Bharadwaj et al. Molecular Cancer
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- A Binding Domain on Mesothelin for CA125/MUC16
- (2008) Osamu Kaneko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started